Amplia Therapeutics – Completion of Recruitment for Phase 2a ACCENT Trial

Release Highlights:

• Amplia Therapeutics has completed the enrolment of 26 patients for the interim analysis of the Phase 2a ACCENT trial, which evaluates the efficacy of narmafotinib combined with standard chemotherapy in advanced pancreatic cancer patients.
• The Phase 1b stage of the trial identified a safe and well-tolerated dosing regimen of 400 mg oral daily narmafotinib, and the Phase 2a trial aims to assess drug efficacy using this regimen.
• The ACCENT trial is being conducted at multiple sites in Australia and South Korea, and preliminary efficacy signals are mirroring positive data from the Phase 1b stage, with interim analysis results expected around Q4 2024.